Efficacy And Safety Of Pegcetacoplan Treatment In Complement-Inhibitor Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From The Phase 3 PRINCE Study (NAPNAP 2022) - Apellis Medical Hub

Efficacy And Safety Of Pegcetacoplan Treatment In Complement-Inhibitor Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From The Phase 3 PRINCE Study

Share Via Email

Back to Conference Resources

PNH Congress Presentations National Association of Pediatric Nurse Practitioners (NAPNAP) 2022

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.